<DOC>
	<DOCNO>NCT01945580</DOCNO>
	<brief_summary>To compare transvaginal repair biologic graft traditional native tissue repair woman surgically treat anterior and/or apical pelvic organ prolapse .</brief_summary>
	<brief_title>Xenform Postmarket Surveillance Study</brief_title>
	<detailed_description>The primary objective evaluate clinical effectiveness transvaginal repair Xenform traditional native tissue repair woman surgically treat anterior and/or apical pelvic organ prolapse . Secondary objective evaluate Xenform-related complication subject report outcome . The primary endpoint study achieve non-inferiority transvaginal repair Xenform native tissue repair 36 month compare baseline . Success base composite objective subjective measure . Additionally , co-primary endpoint study achieve non-inferiority transvaginal repair Xenform native tissue repair safety compare rate serious device serious procedure relate complication baseline 36 month time point . The secondary endpoint study include assessment complication subject report outcome .</detailed_description>
	<mesh_term>Prolapse</mesh_term>
	<mesh_term>Pelvic Organ Prolapse</mesh_term>
	<criteria>Subject female Subject least 18 year age Subject pelvic organ prolapse lead edge beyond hymen . At beyond hymen define POPQ score Ba≥0 ( prolapse anterior compartment alone ) C≥0 ( prolapse apical compartment alone ) C≥1/2 TVL Ba≥0 ( multicompartment prolapse include anterior apical compartment ) . Subject report bothersome bulge see feel per PFDI20 , question 3 , response 2 high ( i.e. , responses `` somewhat '' , `` moderately '' , `` quite bit '' ) Subject subject 's legally authorized representative willing provide write informed consent Subject willing able comply followup regimen Subject pregnant intend become pregnant study Subject active chronic systemic infection include gynecologic infection , untreated urinary tract infection ( UTI ) tissue necrosis Subject history pelvic organ cancer ( e.g . uterine , ovarian , bladder , colorectal cervical ) Subject prior currently undergo radiation , laser therapy , chemotherapy pelvic area Subject take systemic steroid ( within last month ) , immunosuppressive immunomodulatory treatment ( within last 3 month ) Subject systemic connective tissue disease ( e.g . scleroderma , systemic lupus erythematosus ( SLE ) , Marfan syndrome , Ehlers Danlos , collagenosis , polymyositis , polymyalgia rheumatica ) Subject chronic systemic pain include pelvic area chronic focal pain involve pelvis Subject uncontrolled diabetes mellitus ( DM ) Subject know neurologic medical condition affect bladder function ( e.g. , multiple sclerosis , spinal cord injury stroke residual neurologic deficit ) Subject seek obliterative vaginal surgery treatment pelvic organ prolapse ( colpocleisis ) Subject able conform modify dorsal lithotomy position Subject currently participate plan participate another device drug study study Subject know sensitivity Xenform component Subject previous prolapse repair mesh target compartment Subject planning undergo concomitant prolapse repair use mesh nontarget compartment</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>POP</keyword>
	<keyword>Transvaginal</keyword>
	<keyword>Native Tissue Repair</keyword>
	<keyword>Repair Augmented Mesh</keyword>
	<keyword>Biologic Graft</keyword>
	<keyword>Pelvic Organ Prolapse</keyword>
</DOC>